An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
Phase 2
Withdrawn
- Conditions
- Large B-cell LymphomaB-cell Lymphoma
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05929716
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
Phase 2
Recruiting
- Conditions
- Lymphoma
- Interventions
- Radiation: Ultra Low Dose 4 Gy Radiation
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT05929612
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
Phase 1
Recruiting
- Conditions
- Ovarian CancerAdenocarcinomaPancreatic Cancer
- Interventions
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT05922930
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Harmony & Health: A Culturally Adapted Mindbody Intervention to Reduce Sitting Time and Improve Psychosocial Wellbeing in Black Adults
Not Applicable
Recruiting
- Conditions
- Psychosocial
- Interventions
- Behavioral: Harmony & Health program
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 250
- Registration Number
- NCT05922943
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
Phase 2
Recruiting
- Conditions
- Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT05922904
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Development of Brief Positive Affect Treatment (PAT) for Caregivers of Patients with Advanced Cancer
Not yet recruiting
- Conditions
- Cancer
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 150
- Registration Number
- NCT05904782
An Evaluation of the Implementation of the Care and Monitoring at Home Program- A New Paradigm for Acute Care Management of Cancer Patients
Suspended
- Conditions
- Cancer
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT05904899
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)
Phase 2
Withdrawn
- Conditions
- Colorectal CancerColon CancerRectum Cancer
- Interventions
- Drug: RegorafenibDrug: XmAb20717
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05900648
Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05884320
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
HEALTH4CLL2: a Randomized Waitlist Control Trial of Behavioral Interventions in Patients with Chronic Lymphocytic Leukemia
Not Applicable
Recruiting
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Behavioral: QuestionnairesOther: Fit Bit
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05879133
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath